Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. develops engineered cells as medicines for patients, with programs that apply cell engineering, hypoimmune platform technology, and fusogen-based delivery. News about SANA commonly covers its type 1 diabetes cell-replacement work, including UP421 and SC451, and its in vivo CAR T program SG293 for CD19-directed therapy in B-cell cancers and B-cell-mediated autoimmune diseases.
Company updates also include preclinical and clinical data presentations, research collaborations, manufacturing and regulatory preparation, financial results, equity financing activity, executive appointments, and investor conference presentations.
Sana Biotechnology (NASDAQ: SANA) reported 14-month follow-up from a first-in-human, investigator-sponsored study transplanting HIP-modified primary islet cells (UP421) into a patient with type 1 diabetes without immunosuppression.
The transplanted cells showed sustained survival and function, with fasting and MMTT-stimulated C-peptide present at month 14, comparable to the first six months; no safety issues were identified. Sana expects to file an IND for SC451 and initiate a Phase 1 trial as early as this year. Full 14-month data are being presented at ATTD on March 13, 2026.
Sana Biotechnology (NASDAQ: SANA) reported Q4 and full‑year 2025 results, highlighting clinical progress and financing. Key points: UP421 showed one‑year survival and function of hypoimmune islet cells without immunosuppression; NEJM published 12‑week results. Sana raised aggregate gross proceeds of $133.7M, held $138.4M cash at year‑end, and expects runway into late 2026. Company expects IND filing and Phase 1 start for SC451 and first‑in‑human data for SG293 as early as 2026. Reported R&D spend decline and a $44.6M impairment tied to facility strategy.
Sana Biotechnology (NASDAQ: SANA) will present live at two investor conferences in March 2026, with webcasts and 30-day replays available.
Sana will present a business overview and update at the Cowen 46th Annual Health Care Conference on March 2, 2026 at 1:10 p.m. ET and at the Citizens Life Sciences Conference on March 11, 2026 at 1:40 p.m. ET. Webcasts are on the company Investor Relations page and replays remain for 30 days.
Sana Biotechnology (NASDAQ: SANA) appointed Brian Piper as Executive Vice President, Chief Financial Officer effective Feb. 17, 2026. Mr. Piper brings more than 25 years of biopharma finance and operations experience, including CFO roles at Scorpion Therapeutics, Antares Therapeutics, Prelude, and Aevi.
The company expects initial clinical data in 12–18 months for SC451 (type 1 diabetes) and SG293 (B‑cell related disease); management says Piper will help manage capital formation, allocation, and operational execution as these programs advance.
Sana Biotechnology (NASDAQ: SANA) will present at the 44th Annual J.P. Morgan Healthcare Conference with a live webcast on Wednesday, January 14, 2026 at 9:45 a.m. PT.
The presentation will include a business overview and update delivered by Steve Harr, president and chief executive officer. The webcast and a replay will be available on Sana's Investor Relations website, with the replay accessible for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA) reported that Nature Biotechnology published preclinical data showing systemic, in vivo gene editing of human hematopoietic stem and progenitor cells (HSCs) in murine models using Sana’s fusogen virus-like particle (VLP) platform (DOI: 10.1038/s41587-025-02915-2) on Dec 8, 2025. Results demonstrate potent, cell-specific editing in long-term HSCs, editing at two hemoglobinopathy-relevant loci including fetal hemoglobin, and avoidance of off-target delivery to hepatocytes. Sana said the fusogen platform now expands beyond T cells to HSCs and is being used to develop SG293 (a CD8-targeted fusosome to make CD19 CAR T cells in vivo) with an IND filing expected as early as 2027.
Sana Biotechnology (NASDAQ: SANA) will webcast presentations at two investor conferences in December 2025 featuring a business overview and update by Steve Harr, President and CEO.
Sana will present at Citi’s 2025 Global Healthcare Conference on Dec 2, 2025 at 2:30 p.m. ET and at the 8th Annual Evercore Healthcare Conference on Dec 3, 2025 at 2:35 p.m. ET. Live webcasts and replays will be available on Sana’s Investor Relations page at https://sana.com/, with each replay accessible for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA) reported Q3 2025 results and strategic reprioritization focused on SC451 (HIP-modified iPSC-derived islet cells for type 1 diabetes) and SG293 (next‑generation in vivo CAR T).
Key developments: NEJM published positive 12-week data for UP421 showing transplanted HIP-modified islet cells survived, evaded immune detection, and produced C-peptide without immunosuppression. Sana expects to file an IND for SC451 as early as 2026 and an IND for SG293 as early as 2027. The company suspended enrollment and internal investment in its allogeneic CAR T programs SC291 and SC262 to focus resources.
Financials: Cash $153.1M at Sept 30, 2025; raised additional equity in Q3–Q4 2025 and expects a cash runway into late 2026. Non-cash impairment of $44.6M recorded in 2025.
Sana Biotechnology (NASDAQ: SANA) will present at the TD Cowen Immunology & Inflammation Summit on Wednesday, November 12, 2025 at 1:30 p.m. ET. The presentation, given by Steve Harr, President and CEO, will provide a business overview and company update.
The presentation will be webcast and available on Sana's Investor Relations website at https://sana.com/. A replay will be posted at the same location for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA), a company specializing in engineered cell therapies, has announced its participation in four major investor conferences this September 2025.
The company will present business overviews and updates at:
- Citi's Biopharma Back-to-School Conference on September 2 at 3:15 PM ET
- Wells Fargo Healthcare Conference on September 4 at 8:00 AM ET
- Morgan Stanley Global Healthcare Conference on September 8 at 11:30 AM ET
- HC Wainwright Global Investment Conference on September 9 at 9:30 AM ET
All presentations will be available via webcast on Sana's Investor Relations website, with replays accessible for 30 days after each event.